Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Cash from Operations: 2020-2024

Historic Cash from Operations for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to -$43.8 million.

  • Janux Therapeutics' Cash from Operations fell 476.24% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.4 million, marking a year-over-year decrease of 90.37%. This contributed to the annual value of -$43.8 million for FY2024, which is 13.37% up from last year.
  • Per Janux Therapeutics' latest filing, its Cash from Operations stood at -$43.8 million for FY2024, which was up 13.37% from -$50.6 million recorded in FY2023.
  • Over the past 5 years, Janux Therapeutics' Cash from Operations peaked at -$4.4 million during FY2020, and registered a low of -$50.6 million during FY2023.
  • For the 3-year period, Janux Therapeutics' Cash from Operations averaged around -$45.8 million, with its median value being -$43.8 million (2024).
  • Per our database at Business Quant, Janux Therapeutics' Cash from Operations slumped by 288.56% in 2021 and then climbed by 13.37% in 2024.
  • Over the past 5 years, Janux Therapeutics' Cash from Operations (Yearly) stood at -$4.4 million in 2020, then tumbled by 288.56% to -$17.0 million in 2021, then plummeted by 152.84% to -$42.9 million in 2022, then dropped by 17.83% to -$50.6 million in 2023, then grew by 13.37% to -$43.8 million in 2024.